Late-Stage CAHmelia Program in Adult Classic CAH Advancing with Majority of Study Sites Active CAHmelia Program Enhanced Following Discussions with FDA - Primary Data Expected in 2022 Amended Debt Facility with SVB Provides Access Up to Additional $25 Million in Non-Dilutive Financing New Drug
Tildacerfont Led to Significant Reductions in Disease Biomarkers Over 12 Weeks Tildacerfont is First CRF1 Antagonist Studied Beyond Two Weeks in CAH CAHmelia Program Underway and Enrolling Patients in U.S. and Europe SAN FRANCISCO --(BUSINESS WIRE)--Mar. 17, 2021-- Spruce Biosciences, Inc.
SAN FRANCISCO --(BUSINESS WIRE)--Mar. 2, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that data from its Phase 1 and 2
SAN FRANCISCO --(BUSINESS WIRE)--Feb. 17, 2021-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that the company will participate in
-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe - -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent